

CURRICULUM VITAE

Revised: February 2023

Name: Seyyed Nassir Ghaemi
 Address: Tufts Medical Center, Department of Psychiatry, 800 Washington St,
 Boston, MA 02111
 Email: nassir.ghaemi@tufts.edu
 Phone: 617-599-9184
 Citizenship US

Academic Appointments

Current appointments

07/2008-current Professor of Psychiatry and Pharmacology, Tufts University
 School of Medicine
 07/2008-current Lecturer on Psychiatry, Harvard Medical School

Past appointments

06/2005-06/2008 Associate Professor, Department of Psychiatry, Emory University
 School of Medicine
 06/2000-06/2005 Assistant Professor of Psychiatry, Harvard Medical School
 08/1998-05/2000 Instructor in Psychiatry, Harvard Medical School
 10/1996-07/1998 Research Assistant Professor of Psychiatry, George Washington
 University
 08/1995-10/1996 Assistant Professor of Psychiatry, Medical College of Virginia,
 Virginia Commonwealth University
 06/2005-06/2008 Associate Professor, Rollins School of Public Health, Emory Univ.
 07/2007-2008 Collaborating Lecturer, Department of Psychiatry, Universidad
 Autonoma de Madrid, Madrid, Spain
 09/2003-05/2004 Visiting Professor of Philosophy, Center for Cognitive Studies,
 Tufts University
 09/1999-05/2000 Visiting Fellow, Center for Cognitive Studies, Department of
 Philosophy, Tufts University
 10/1996-05/1997 Clinical Assistant Professor of Psychiatry, Georgetown University
 07/1991-07/1995 Clinical Fellow in Psychiatry, Harvard University
 07/1990-07/1991 Clinical Fellow in Medicine, Harvard University

Other Appointments

10/2017-5/2021 Director, Translational Medicine-Neuroscience, Novartis Institutes
 for Biomedical Research, Cambridge, MA

5/2016 – 10/2017	Associate Medical Director, Expert Behavioral Care Program, Advance Medical Inc., Westwood, MA
07/2008- 10/2017	Director, Mood Disorders Program, Department of Psychiatry, Tufts Medical Center
06/2005-06/2008	Director, Bipolar Disorder Research Program, Department of Psychiatry, Emory University School of Medicine
06/2005-06/2008	Director, Resident Psychopharmacology Clinic, Department of Psychiatry, Emory University School of Medicine
06/2000-06/2005	Director, Bipolar Disorder Research Program, Cambridge Health Alliance
08/2003-06/2005	Co-director, Psychopharmacology Research Program, Cambridge Health Alliance
08/1998-05/2000	Assistant in Psychiatry, MGH
08/1998-05/2000	Assistant Director, Harvard Bipolar Research Program, MGH
10/1996-05/1997	Associate Director, Consultation/Liaison Service, Georgetown University Hospital
10/1996-07/1998	Attending Psychiatrist, George Washington University (GWU) Adult Outpatient Psychiatry Clinic
10/1996-07/1998	Director, Bipolar Disorder Research Program, GWU
10/1996-07/1998	Senior Investigator, Center on Neuroscience, Medical Progress, and Society, GWU, Washington, DC
08/1995-10/1996	Attending Psychiatrist, Medical College of Virginia (MCV) Hospitals
08/1995-10/1996	Director, Affective Disorders Program, MCV
08/1995-10/1996	Co-investigator, Unipolar Mood Disorders Institute, Virginia Commonwealth University, MCV
07/1994-07/1995	Research Fellow, Psychopharmacology Program, MGH
07/1994-07/1995	Assistant Attending Psychiatrist, McLean Hospital
05/1993	Resident in Psychiatry, Consultation/Liaison Service, MGH
07/1993-07/1994	Chief Resident, Psychopharmacology Service, McLean Hospital
07/1990-07/1991	Resident in Internal Medicine, Massachusetts General Hospital (MGH)
07/1991-07/1994	Resident in Adult Psychiatry, McLean Hospital

Leadership experience

10/2017-5/2021	<p>Translational Medicine Expert, Neuroscience, Novartis Institutes for Biomedical Research</p> <p>Led two clinical trial teams for conduct of phase II trials. As medical lead, closely interacted with clinical trial lead, and with principal investigators at dozens of research sites.</p> <p>Clinical expert in multiple research project teams in drug discovery, interacting with multiple leaders in other line function (chemistry, neurobiology, biomarkers, regulatory, patent law, commercial, development).</p>
5/2016 – 10/2017	Associate Medical Director, Expert Behavioral Care Program, Advance Medical Inc., Westwood, MA

Founded a new program in psychiatry for expert second opinion company, as a free benefit for major companies and employers (e.g., Google, Fidelity, Capital One). Hired 4 psychiatrists as part-employees to oversee the psychiatric expert opinion work. Interacted with them and with upper management at Advance Medical to organize and conduct the behavioral health program. Continue to serve as an expert consultant in psychiatry to the company, now merged with Teladoc Health, after leaving to take full-time employment at Novartis.

07/2008- 10/2017 Director, Mood Disorders Program, Department of Psychiatry, Tufts Medical Center
Ran full-time research and clinical program, with two research assistant, and in some years a psychiatrist research fellow. Founded, directed, funded, and led this program until departure for Novartis.

Leadership training courses (Novartis)

11/2019 Active Listening
12/2019 Giving Feedback
12/2019 Transformational Leadership
All online except as specified

Research training course (Novartis)

1/2018: Drug discovery and development: Project simulation
10/2019: Transitioning projects from early to full drug development
Courses were in-person with one day duration each.

Licensure/Boards

07/1988-05/1990 Passed National Medical Board Examination, Parts I, II, III
07/1990-07/1991 Limited Medical License, Commonwealth of Massachusetts
07/1991-07/1996 Permanent Medical License, Commonwealth of Massachusetts, #75077
08/1995-08/1997 Permanent Medical License, Commonwealth of Virginia, #0101052735
10/1997-07/1998 Permanent Medical License, District of Columbia, #21861
07/1998-06/2005 Permanent Medical License, Commonwealth of Massachusetts, #75077
06/2005-07/2008 Permanent Medical License, State of Georgia, #056289
07/2008- Permanent Medical License, Commonwealth of Massachusetts, #75077

Specialty Boards

05/1996-12/2006 Board-certified, American Board of Psychiatry and Neurology, #42407

03/2007-12/2017	Re-certified, American Board of Psychiatry and Neurology, #42407
12/2018-current	Re-certified, American Board of Psychiatry and Neurology, #42407

Education

05/1986	B.A. History, George Mason University, Fairfax, Virginia
05/1990	M.D. Medicine, Medical College of Virginia, Richmond, Virginia
08/2001	M.A. Philosophy, Tufts University, Medford, Massachusetts
05/2004	M.P.H., Harvard School of Public Health, Boston, MA

Postgraduate Training

07/1990-07/1991	Resident in Internal Medicine, Massachusetts General Hospital
07/1991-07/1994	Resident in Adult Psychiatry, McLean Hospital
07/1993-07/1994	Chief Resident, Psychopharmacology Program, McLean Hospital
07/1994-07/1995	Research Fellow, Graduate Psychopharmacology Program, Massachusetts General Hospital

Committee Memberships

National and International

05/1999-07/2012	Member, Executive Committee, Association for the Advancement of Philosophy and Psychiatry.
05/1999-05/2000	Chair, Recruitment Committee, Association for the Advancement of Philosophy and Psychiatry
07/2001-07/2004	Member, Advisory Board, Families for Depression Awareness
07/2001-07/2005	Member, Task Force to Update the Ethics Annotations, American Psychiatric Association
07/2004-02/2008	Chair, International Diagnostic Guidelines Project for Bipolar Disorder, International Society for Bipolar Disorders
07/2015-07/2016	Member, Steering Committee on Practice Guidelines, American Psychiatric Association

Regional and State

05/1990-05/1993	Greater Boston Physicians for Social Responsibility (PSR) Elected member, Steering Committee.
05/2002-05/2005	Professional Advisor, National Depressive and Manic Depressive Association, New Hampshire Chapter, Nashua, NH
05/2004-05/2005	Member, Continuing Medical Education Committee, Massachusetts Psychiatric Society
11/2008-11/2010	Elected member, Executive committee, Massachusetts Psychiatric Society

Institutional

07/1991-07/1992	Residency Education Committee, McLean Hospital
07/1991-07/1994	Residents Association, McLean Hospital

07/1991-07/1994	Affirmative Action Committee, McLean Hospital
05/1999-05/2000	Member, Grand Rounds Committee, MGH
06/2000-06/2005	Member, Research Committee, Cambridge Health Alliance
06/2001-06/2005	Member, Institutional Review Board, Cambridge Health Alliance
06/2002-06/2005	Member, Grand Rounds Committee, Cambridge Health Alliance
06/2002-06/2005	Member, Residency Education Committee, Cambridge Health Alliance

Editorial Boards and Editorships

7/2015 -	Associate Editor, Acta Psychiatrica Scandinavica
1/2015 -	Founding Editor, The Psychiatry Letter (website ongoing; monthly newsletter through 12/2018)
07/1997-07/2005	International Drug Therapy Newsletter (Frank Ayd, Jr., MD, ed)
07/1997	Lexicon of Psychiatry, Neurology, and the Neurosciences (Ayd)
07/2000-	Bipolar Disorders
07/2003-	Acta Psychiatrica Scandinavica
07/2004-	Philosophy, Psychiatry, Psychology
07/2004- 07/2012	BP magazine
07/2005-07/2010	Psychopathology
07/2005- 07/2012	Acta Medica Iranica
07/2005-	Revista de Trastornos Afectivos
07/2006-	Journal of Affective Disorders
07/2008-	Annals of Clinical Psychiatry
07/2013-	Australian and New Zealand Journal of Psychiatry
07/2013-	International Journal of Bipolar Disorders

Manuscript Reviewer

07/1997-	Archives of General Psychiatry
07/1997	Mayo Clinic Proceedings
07/1997	Psychopharmacology Bulletin
07/1998	Psychiatry: Interpersonal and Biological Processes
07/1998-	Journal of Clinical Psychiatry
07/1998	Psychosomatics
07/1998-	Journal of Affective Disorders
07/1998-	Philosophy, Psychiatry, Psychology
07/1998-	Bipolar Disorders
07/1998	CNS Therapeutics
07/1998-	Journal of Clinical Psychopharmacology
07/2000-	European Archives of Psychiatry and Clinical Neuroscience
07/2000-	Acta Psychiatrica Scandinavica
07/2001-	Journal of Clinical Psychopharmacology
07/2002-	Progress in Biological Psychiatry and Neuropsychopharmacology
07/2004-	American Journal of Psychiatry
07/2004-	Neuropsychopharmacology
07/2004-	Psychopathology
07/2005-	Molecular Psychiatry
07/2005-	British Journal of Psychiatry

Honors and Awards

05/1984	Charles and Polly Weber History Scholarship, George Mason University
05/1984-05/1986	Member, Alpha Chi National Collegiate Honor Society
10/1987	Dean's Book Award in Behavioral Science, Medical College of Virginia
12/1987	Merck Manual Award in Hematology, Medical College of Virginia
05/1988	Sidney Barham Scholarship, Medical College of Virginia
07/1988	A. D. Williams Fellowship in Behavior Genetics, Medical College of Virginia
10/1989	Medical College of Virginia-King's College (London) Exchange Fellowship in Neurology
07/1987-07/1990	Member, Alpha Omicron Alpha National Medical Honor Society
05/1993	Co-awarded the Karl Jaspers prize of the Association for the Advancement of Philosophy and Psychiatry, a resident paper award, for "Mind/Brain Theories and Their Discontents," written with Godehard Oepen, M. D.
05/1994	APA-Dista Resident Research Paper Award, "Lack of Insight in Psychotic and Affective Disorders: A Review of the Literature and an Empirical Study of Bipolar Disorder", American Psychiatric Association
09/1994	Congress Fellowship, 7 th Annual U. S. Psychiatric and Mental Health Congress, Washington, D. C.
06/1995	New Investigator Award, National Clinical Drug Evaluation Unit (NCDEU) Meeting, National Institute of Mental Health, Orlando, Florida
09/1996	Outstanding Service Award, Virginia Alliance for the Mentally Ill
05/2003	Best Lecturer, Cambridge Health Alliance, PGY-4 resident class
05/2005	Distinguished Fellow, American Psychiatric Association
05/2007	Best Review Article of the Year, <i>Primary Psychiatry</i> , "Hippocrates and Prozac: The controversy about antidepressants in bipolar disorder," November 2006
5/2007	Best Lecturer, Emory University, PGY-4 Resident Class
9/2010	Nominated for British Medical Association book award in psychiatry, "Highly commended", A Clinician's Guide to Statistics and Epidemiology in Mental Health
10/2010	Recipient, First Quantia MD Community Choice Award for medical education. Recipients each received a 5-star rating from over 1,000 unique QuantiaMD members based on ratings of their online CME content. 16 winners out of over 1,200 physician presenters on Quantia MD. I was the only psychiatrist to win the award.
6/2011	Recipient, Irene Jacob Award for Excellence in Professional

	Service to DBSA (Depression and Bipolar Support Alliance) – Boston
5/2020	Recipient, PROSE Award for Excellence in the Biological and Life Sciences, American Association of Publishers. For <i>Clinical Psychopharmacology: Principles and Practice</i> , Oxford University Press, 2019
4/2021	Outstanding Psychiatrist – Research, Massachusetts Psychiatric Society
5/2022	Distinguished Life Fellow, American Psychiatric Association

Society Memberships

07/1990-07/1991 – 2015	American Psychiatric Association	Distinguished Fellow
	Association for the Advancement of Philosophy and Psychiatry	Member
07/1990-07/1991	American Medical Association	Member
07/1990-07/1991	Massachusetts Medical Society	Member
07/1990-07/1993	Physicians for Social Responsibility	Officer
07/1991-07/1995	Boston Society of Neurology and Psychiatry	Member
07/1991-07/1994	Massachusetts Psychiatric Society	Member
07/1995-07/2000	American Philosophical Association	Member
07/1995-07/1997	Association of American Medical Colleges	Member
07/1995-07/1997	Virginia Psychiatric Society	Member
07/1997-2014	Karl Jaspers Society	Member
2014-	Karl Jaspers Society	Executive Cmte Member-at-Large
07/1998-	Massachusetts Psychiatric Society	Member
07/1998	Washington School of Psychiatry	Member
07/1999-	International Society for Bipolar Disorders	Member
07/2000-current	Collegium Internationale Neuropsychopharmacologicum	Member
07/2000-07/2005	Society for Biological Psychiatry	Member
07/2000-07/2002	New York Academy of Sciences	Member
07/2001-	International Society for Affective Disorders	Fellow
07/2001-07/2003	American Academy of Clinical Psychiatrists	Member
07/2003-07/2005	History of Science Society	Member
07/2003-07/2005	American Association for the History of Medicine	Member
07/2003-07/2005	Charles S. Peirce Society	Member
2008-2010	American Medical Association	Member
2020-	Royal Society of Medicine (UK)	Fellow

Grant Study Section memberships

2011 - Brain disorders and related neuroscience panel study section – participant, Yvonne Bennett, Scientific review officer, NIMH

2012 – Complementary and Alternative Medicine therapies study section – participant, Hungyi Shau, Scientific review officer, NIMH

2014 – Mood disorders study section – participant, Veterans Administration

2018 – current PHRMA Foundation, Pharmacology research awards, Washington DC

Research Focus

My main research focus has been on the role of antidepressants in the treatment of bipolar illness. Other foci of research include methodological issues in psychiatric research (epidemiology), clinical studies of promising mood-stabilizing agents (e.g., atypical antipsychotics, novel anticonvulsants), and nosology/phenomenology (defining the bipolar spectrum, screening tools, lack of insight). I also have worked in early drug discovery at Novartis and led two phase II proof-of-concept trials on a new NMDA negative allosteric modulator for refractory depression, and a digital cognitive behavioral application for schizophrenia. I also guided multiple other drug programs from preclinical phases to phase I and phase II start-up.

Academic Grant Support

Previous Federal Support

7/2007-6/2013, NIMH, R01 (MH-0708060)

“Treatment for bipolar depression: Acute & prophylactic efficacy with citalopram,”

Principal investigator, \$2,480,650

2001-06 NIMH, MH-64189, K23 Research Career Development Award, “Long-term antidepressant outcome in bipolar disorder”, Principal investigator, \$923,080

2000-05 NIMH, RFP No. NIMH-98-DS-0001, “Systematic Treatment Enhancement Program for Bipolar Disorder, STEP-BD”, Co-investigator (Gary Sachs, PI), \$21,000,000 (I served as director of the Cambridge Health Alliance site, part of the MGH-led Partners site for that multi-center study)

Pharmaceutical Industry Research Activities

1/2018-9/2019 - Completed phase II Proof of Concept Trial: “A Randomized, Sham-Controlled Study of PEA-004 as an adjunct to standard-of-care treatment for schizophrenia”. Role: Medical Lead. Designed, organized, and conducted 6 site (n=110) US-based multi-center RCT of a digital therapeutic of cognitive-behavioral therapy for acute psychotic exacerbation in schizophrenia. Study was completed in 7 months (twice as fast as usual PoCs at NIBR) at about one-fifth the usual cost.

7/2018-11/19 - Completed phase II Proof of Concept Trial: “A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of MIJ821 in patients with treatment-resistant depression.” Designed, organized, and conducted 8 site US-based and 4 site Spain-based (n=66) multi-center RCT of a new NMDA negative allosteric modulator for acute unipolar treatment-refractory depression. Study was completed in 9 months to PoC result.

10/17-5/21: Active clinical research member of drug discovery teams with novel agents

for schizophrenia, bipolar illness, and dementia-related psychosis.

6/2018-12/19: Active clinical research leader of digital therapeutics team for cognitive-behavioral digital intervention for depression in multiple sclerosis.

7/2019-12/19: Member of development transition team for MIJ821 for phase IIb and phase III studies.

Formal Teaching

Medical student teaching

Tufts University School of Medicine

2008-17 Mood disorders didactic teaching, lecture for 3rd year medical students on psychiatry rotation, about 40 students, 1 hour monthly

2008-17 Outpatient psychiatry supervision, for 3 3rd year medical students during psychiatry rotation, 1 hour weekly

Harvard Medical School

2008-2009 2nd year student mood disorder seminar, part of Psychopathology and Introduction to Clinical Psychiatry course, taught lecture on bipolar disorder, one per semester, class of about 100 students

Emory University

06/2005-2008 2nd year medical student lecture on bipolar disorder, 1 hour

Harvard Medical School

07/2004-07/2005 2nd year student mood disorder seminar, part of Psychopathology and Introduction to Clinical Psychiatry course, taught lecture on bipolar disorder, one per semester, class of about 100 students

07/1998-07/2000 Lecturer, Rotating 3rd year medical student psychiatry course, MGH, 1 hour per month

07/1993-07/1994 Clinical Rotation in Psychiatry (3rd Year Students), McLean Hospital Lecturer, "Diagnosis and treatment of psychotic disorders," 6-8 medical students/month, 1 hour/week

07/1992-07/1994 Psychiatry 700 Course (2nd Year Students), Preceptor, McLean Hospital, 1 student/month, 3 hours/month

07/1992-07/1994 Clinical Rotation in Psychiatry (3rd Year Students), McLean Hospital Preceptor, McLean Hospital, 1 student/month, 1 hour/week

George Washington University

10/1996-07/1998 3rd year medical student psychiatry rotation supervision
Individual supervision, 3 students for 2 months twice per year, 1 hour/week

- 07/1998 2nd year medical student Practice of Medicine course instructor, small group sessions, 4 3-hour sessions every year
- 07/1997-07/1998 Instructor, Diagnosis and Treatment of Mood Disorders, 3rd year medical student psychiatry rotation lecture, 1 hour/monthly

Georgetown University

- 07/1996-07/1997 Instructor, Diagnosis and Treatment of Mood Disorders, 3rd year medical student psychiatry rotation lecture, 1 hour/monthly

Medical College of Virginia

- 07/1996 Discussion group leader, M-II behavioral science course on human development, 4 1-hour sessions every 6 months
- 07/1996 Preceptor, M-II interviewing course on the mental status examination, 2 4-hour blocs every 6 months
- 07/1995-07/1996 Lecture on affective disorders for M-III students, 1 hour every 6 weeks
- 07/1995-07/1996 Organized and taught M-II lecture bloc on affective disorders, 4 hours/year
- 07/1995-07/1996 3rd-Year Medical Student Affective Disorders Inpatient Rotation Organizer and supervisor of daily rounds and individual supervision, 1 student monthly, 10 hours/week
- 07/1995-07/1996 1st-Year Medical Student Introduction to Clinical Medicine Course Presenter in collaboration with faculty from primary care medicine, 4 afternoon sessions in the course of 1 year

Residency teaching

Tufts Medical Center

- 2010-current Director and lecturer, Advanced Psychopharmacology course, one hour biweekly, for 3rd and 4th year residents, one semester yearly
- 2010-2012 Director and lecturer, Psychopathology course, one hour biweekly, for 3rd and 4th year residents, one semester yearly
- 2008-18 Director and lecturer, History and Philosophy of Psychiatry, one hour biweekly, for 3rd and 4th year psychiatry residents, full year course
- 2009-17 Director and lecturer, Evidence-based psychiatry course, one hour biweekly, for 3rd and 4th year residents, one semester yearly

Cambridge Health Alliance

- 2008-current Lecturer, Advanced Psychopharmacology course, one hour monthly, for 3rd and 4th year residents

Emory University

- 06/2005-08 Principal supervisor, Resident Psychopharmacology Clinic, 3rd year residents, 2 group supervision sessions, one hour each, weekly
- 06/2005-08 Course director, History of Psychiatry, 4th year residents, four one hour

- lectures yearly
- 06/2005-08 Lecturer, Mood Disorders Course, PGY-1 residents, “Diagnosis of bipolar disorder”, Treatment of bipolar disorder”, 2 one-hour lectures yearly
- 06/2005-08 Lecturer, Evidence-based medicine course, PGY-3 residents, “Levels of evidence and understanding clinical research, 2 one-hour lectures yearly
- 06/2005-08 Founder and group leader, Psychopharmacology journal club, one hour monthly, all PGY 1-4 resident classes

Cambridge Health Alliance

- 06/2000-06/2005 Course director, Outpatient Psychopharmacology Course, 3rd year psychiatry residents, organize schedule, lectures given by me weekly for 1 hour
- 06/2000-06/2005 Psychopharmacology supervisor, one PGY-3 resident and one PGY-4 resident, 2 hours biweekly
- 06/2000-06/2002 Co-course director, Research seminar, 3rd year residents, organize schedule with James Beck MD, 4 lectures for one hour each given by me over a 2 month period
- 06/2002-06/2005 Journal Club Leader, PGY-3 and PGY-4 Residents, 1 1-hr session/week, 11 Residents
- 07/2003-06/2005 History of psychiatry course, PGY-1 residents, 1 1 hour session/week for 4 weeks, co-taught with Leston Havens MD
- 07/2004-06/2005 Concepts of psychiatry course, PGY-III residents, 1 1 hour session/week for 4 weeks
- 07/2004-06/2005 Course director, Evidence based medicine course, 3rd year psychiatry residents, organize schedules, lectures given by me weekly for 1 hour

Massachusetts General Hospital

- 10/1998-05/2000 Lecturer and supervisor, PGY-III bipolar disorder outpatient clinic rotation, 1 hour per week, 4 months/year
- 07/1999-05/2000 Psychopharmacology supervisor, one PGY-II resident, 1 hour biweekly

George Washington University

- 10/1996-07/1998 Instructor, Psychopharmacology course, 3rd year psychiatry resident course, 4 1-hour lectures monthly
- 10/1997-07/1998 PGY-3 resident psychopharmacology supervision
Individual supervision, 1 resident every 6 months, 2 hours/month
- 07/1998 Course director, Psychopharmacology and Neuroscience, 2nd year psychiatry residents, organize weekly lectures, lectures given by me twice monthly for 1 hour

Georgetown University

- 10/1996-05/1997 Instructor, Psychopharmacology in Psychiatric Consultation, 3rd year medical student and 3rd year psychiatry resident course, 4 1 hour lectures monthly
- 10/1996-05/1997 PGY-3 Resident Psychiatry Consultation Service Rotation

Supervisor of thrice weekly rounds and individual supervision, 3 resident every 6 months, 10 hours/week

Medical College of Virginia

- 07/1995-07/1996 PGY-I Resident Affective Disorders Inpatient Rotation
Organizer and supervisor of daily rounds and individual supervision, 1 resident every 2 months, 10 hours/week
- 07/1995-07/1996 PGY-II Resident Affective Disorders Outpatient Rotation
Organizer and supervisor of weekly clinic and individual supervision, 1 resident every 2 months, 4 hours/week
- 07/1995-07/1996 Psychotherapy supervision, 1 hour weekly, 1 resident per year
- 07/1995-07/1996 Organized and taught PGY-II lecture bloc on affective disorders, 12 hours/year
- 07/1995-07/1996 Co-organized and co-taught PGY-II and PGY-IV lecture bloc on psychopharmacology with Douglas Brink PharmD, 12 hours/year
- 07/1995-07/1996 Co-organized and co-taught inpatient psychopharmacology case conference, once every 2 months, with G. Sampath MD, 6 hours/year

McLean Hospital

- 07/1993 Psychopharmacology Summer Seminar Series Organizer and instructor, 1 hour/week for 2 months
- 07/1993-07/1994 PGY-III Resident Psychopharmacology Consult Rotation
Organizer and supervisor of rounds, 3 residents every 3 months, 1 psychopharmacology fellow, 1 neurology resident, 3 hours/week
- 07/1993-07/1994 Psychopharmacology consult rotation for 3rd year neurology residents from Massachusetts General Hospital, coordinator and supervisor, 1 resident every 2 months, 1 hour/week
- 07/1993-07/1994 Psychopharmacology Lunch Conference
Organizer, 30-60 residents and staff members, 1 hour/week
- 07/1993-07/1994 Psychopharmacology Journal Club
Organizer and presenter, 10 residents, 1 hour/month

Public health and epidemiology teaching

- 09/2006-12/2006 Life in the Age of Prozac: Psychopharmacology and the Self, weekly course for the Neuroscience and Behavioral Biology major, Institute for Liberal Arts, Emory University, Rollins School for Public Health, Department of Behavioral Sciences and Health Education, Course director and sole teacher, 15 graduate and undergraduate students
- 01/2007-05/2007 Mental Illness, Public Health, and American Culture in Interdisciplinary Perspective. Emory University, Rollins School for Public Health, Department of Behavioral Sciences and Health Education, Co-director and co-teacher with Howard Kushner PhD, 20 graduate and undergraduate students

Other categories

- 2012- current “Essential Psychopharmacology”, Week-long seminar organizer and sole speaker, Harvard Medical School, Department of Continuing Education, 15 hours/year. Given every other summer
- 2010- 2013 “Bipolar Disorder: Current and Emerging Treatments for Depression”, Invited presenter, Psychopharmacology: A Master Class, Harvard Medical School, Department of Continuing Education. Given each spring in April.
- 2009-current “Becoming a Master Clinician”, Week-long seminar organizer and sole speaker, Annual Cape Cod Summer Symposia, New England Education Institute, 15 hours/year. Given each summer.

Selected Invitations/Lectures in National or International Conferences (last seven years only)

- 5/2013 Chair and speaker, Symposium: “Antidepressants in major depressive disorder: The efficacy debate”, Lecture: “Nosology and antidepressant efficacy”, American Psychiatric Association annual meeting, San Francisco, CA.
- 5/2013 Chair and speaker, Symposium: “Bipolar disorder: An update on diagnosis and treatment”, Lecture: “Update on antidepressants in bipolar depression”, American Psychiatric Association annual meeting, San Francisco, CA.
- 5/2013 Speaker, Symposium: “Achievement, innovation, and leadership in the affective spectrum”, Lecture: “Mood illnesses and leadership”, American Psychiatric Association annual meeting, San Francisco, CA.
- 6/2013 Chair and participant: “Brainstorming session: Research diagnostic criteria for bipolar disorder: A proposal”, International Congress on Bipolar Disorders, Miami, FL.
- 6/2013 Chair and participant: “Brainstorming session: What is the Proper Role of Antidepressants in the Longer Term Management of Bipolar Disorder? A Debate and Discussion”, International Congress on Bipolar Disorders, Miami, FL.
- 2/2014 Invited panelist, “Leadership and mental illness: King Lear”, National Theatre Forum, National Theatre, South Bank, London, England.
- 2/2014 Week long course: “Clinical Psychopharmacology: Principles and Practice”, The 21st Annual Florida Symposia, New England Educational Institute, Marco Island, FL, February 17-21, 2014.
- 3/2104 Invited guest expert, “Creativity and psychopathology”, Dissertation defense at the Karolinska Institute, Stockholm, Sweden
- 4/2014 Invited debate participant, “Antipsychotics are not mood stabilizers”, College of Psychiatric and Neurologic Pharmacists annual meeting, Phoenix Arizona

- 5/2014 Invited lecturer, Presidential symposium, "American perspectives on DSM nosology", American Psychiatric Association annual meeting, New York.
- 5/2014 Chair and speaker, Invited symposium: "Bipolar disorder: An update on diagnosis and treatment", Lecture: "Overdiagnosis or underdiagnosis: Clarifying the debate?", American Psychiatric Association annual meeting, New York.
- 7/2014 Weeklong seminar, "Becoming a master clinician," New England Educational Institute, Cape Cod, MA
- 8/2014 Weeklong seminar, "Psychopharmacology," Harvard Medical School CME, Martha's Vineyard, MA
- 10/2014 Plenary speaker, "Manic-depressive illness and leadership," Opening lecture, Latin American Psychiatric Association (APAL), Cartagena, Colombia
- 5/2015 Chair and speaker, Symposium: "Bipolar disorder: An update on diagnosis and treatment", Lecture: "Update on antidepressants in bipolar depression", American Psychiatric Association annual meeting, Toronto, Canada
- 5/2015 Chair and speaker, Symposium: "DSM: History and Critique", Lecture: "Pragmatism, postmodernism, and DSM", American Psychiatric Association annual meeting, Toronto, Canada
- 7/2015 Weeklong seminar, "Becoming a master clinician," New England Educational Institute, Cape Cod, MA
- 8/2015 Weeklong seminar, "Psychopharmacology," Harvard Medical School CME, Martha's Vineyard, MA
- 9/2015 Invited speaker, "The bipolar spectrum: conceptions and misconceptions," Center for Addictions and Mental Health, University of Toronto
- 10/2015 Invited speaker, James O'Neill lecture series, "A First-Rate Madness," Saginaw Valley State University, Saginaw, Michigan
- 11/2015 Invited speaker, "Stigma and psychiatric illness," The Kennedy Forum, Chicago
- 12/2015 Invited speaker, "The bipolar spectrum," Princeton House, University Medical Center, Robert Wood Johnson Medical School, Princeton NJ
- 2/2016 Invited speaker, Sharfstein lecture series, "DSM: Past and present," Shepherd Pratt Hospital, Towson, Maryland
- 4/2016 Invited speaker, "Treating anxiety and depression in persons with cardiovascular disease and dementia," Experts Convergence for Health Outcomes (ECHO) summit, Manila Philippines
- 6/2016 Invited speaker, "Manic-depressive illness: Diagnostic aspects", University of Chile, Santiago Chile
- 7/2016 Weeklong seminar, "Becoming a master clinician," New England Educational Institute, Cape Cod, MA
- 8/2016 Weeklong seminar, "Psychopharmacology," Harvard Medical School CME, Martha's Vineyard, MA
- 9/2016 Invited speaker, "Bipolar illness and antidepressants: Risk management," Pennsylvania Psychiatric Association, Philadelphia

- 10/2016 Invited speaker, “Antidepressants in Bipolar Depression: An Update,” U.S. Psychiatric and Mental Health Congress, San Antonio, Texas October 23, 2016.
- 11/2016 Invited speaker, “Manic-depressive illness”, St. Paul’s Hospital grand rounds, Vancouver, Canada
- 11/2016 Invited speaker, “Manic-depressive illness: Diagnosis and treatment,” All-day conference, University of Parma, Piacenza, Italy
- 11/2016 Invited speaker, “Manic-depressive illness: Diagnosis and treatment,” University of Rome, Rome Italy
- 5/2017 Organizer and chairman, “The Goldwater Rule: Pro and Con,” Annual meeting of the American Psychiatric Association, San Diego, CA
- 5/2017 Invited speaker, “Commentary: Lithium,” Annual meeting of the American Psychiatric Association, San Diego, CA
- 6/2017 Organizer and chairman, “Adult ADD and bipolar illness,” International Society for Bipolar Disorders annual meeting, Washington DC
- 7/2017 Weeklong seminar, “Becoming a master clinician,” New England Educational Institute, Cape Cod, MA
- 8/2017 Weeklong seminar, “Psychopharmacology,” Harvard Medical School CME, Martha’s Vineyard, MA
- 10/2017 Plenary speaker, “Depression: A new approach,” US Psychiatric Congress, New Orleans
- 10/2017 Invited speaker, “Depression: A new approach,” Annual Psychopharmacology Update, Massachusetts Psychiatric Society
- 10/2017 Weeklong seminar, “Psychopharmacology,” New England Educational Institute, Santa Fe, NM
- 1/2018 Grand rounds, “Depression: A new approach,” Department of Psychiatry, Penn State School of Medicine, Hershey, PA
- 1/2018 Co-organizer and speaker, “An overview of depression: Clinical complexities in primary care,” with Jim Phelps MD, Pri-Med annual primary care conference, Orlando, FL
- 3/2018 Keynote speaker, “A first-rate madness: Manic-depressive illness and leadership,” International Society for Bipolar Disorders annual meeting, Mexico City, Mexico
- 5/2018 Speaker, “Commentary: The biopsychosocial model,” Annual meeting of the American Psychiatric Association, New York, NY
- 6/2018 Weeklong seminar, “Becoming a master clinician,” New England Educational Institute, Cape Cod, MA
- 10/2018 Plenary speaker, “Debate on antidepressants in bipolar depression,” US Psychiatric Congress, Orlando, FL
- 10/2018 Invited speaker, “DSM: History and critique,” Alabama Psychiatric Association annual meeting, Mobile, AL
- 10/2018 Invited speaker, James O’Neill lecture series, “Psychiatric profiles of presidential leadership,” Saginaw Valley State University, Saginaw, Michigan
- 5/2019 Chairman and speaker, “Political leadership and the role of psychiatry,” Annual meeting of the American Psychiatric Association, San Francisco

- 5/2019 Co-chairman and speaker, “Developing psychiatric drugs: Can we do better?” Annual meeting of the American Psychiatric Association, San Francisco
- 5/2019 Co-chairman, “Chronic traumatic encephalopathy: Challenges for psychiatry,” Annual meeting of the American Psychiatric Association, San Francisco
- 10/2019 Presenter, “Antidepressants in bipolar depression: A debate,” US Psychiatric Congress, San Diego
- 8/2020 Presenter, “The concepts of psychiatry applied to clinical practice,” University of Chile, Santiago, virtual
- 10/2020 Grand Rounds, “The concepts of psychiatry: Critique and solution,” University of North Carolina, Mountain Area Health Education Center, Asheville, NC, virtual.
- 10/2020 Presenter, 2020 Psychiatric Times Annual World CME Conference, “Antidepressants in bipolar depression: A debate,” and “Combination therapy in bipolar disorder,” virtual.
- 11/2020 Presenter, “Core clinical trial design issues that prevent us from developing effective and transformative drugs”, 3rd Neuropsychiatric Drug Development Summit, Boston, virtual.
- 11/2020 Guest speaker, “Validity of the manic-depressive spectrum, and its characteristics,” In “Bipolaridad: Condicion, espectro, o trastorno? Mesa Redonda con Nassir Ghaemi,” (Bipolarity: Condition, spectrum, or disorder. Roundtable with Nassir Ghaemi), Lima, Peru, virtual.
- 11/2020 Grand rounds, “The concepts of psychiatry applied to clinical practice,” Queens University, Ontario, Canada, virtual.
- 4/2021 “Truths and fallacies of psychopharmacology,” speaker, annual meeting of New Hampshire Psychiatric Society, virtual
- 5/2021 Chairman, APA presidential symposium, “The psychology of racism and nonviolence”, Annual meeting of the American Psychiatric Association, Los Angeles, virtual
- 5/2021 Co-chairman and speaker, “Making sense of anti-psychiatry in the 21st century,” Annual meeting of the American Psychiatric Association, Los Angeles, virtual
- 5/2021 Speaker, “Mixed states in mood disorders: An update for research and practice,” Annual meeting of the American Psychiatric Association, Los Angeles, virtual

Other Activities

- 03/1991 Volunteer co-organizer, Conference on Biological Weapons, Massachusetts Institute of Technology, March, 1991. Physicians for Social Responsibility
- 07/1993 Volunteer consulting psychiatrist, Boston Health Care for the Homeless Project, Katherine McInnis House, Roxbury, Massachusetts
- 07/1992-07/1995 Psychopharmacology consultant, led weekly meetings, Greater Boston Manic-Depressive and Depressive Association (MDDA)

07/1994	Member, Issues Task Force; Member, Health Care Policy Task Force; Mark Roosevelt for Governor campaign, Massachusetts
10/1995	Co-leader, National Depression Screening Day, Medical College of Virginia, Richmond, VA
07/1995-07/1998	Member, Virginia Alliance for the Mentally Ill (VAMI)
12/1996	Invited written testimony, State Senate of the Commonwealth of Virginia, Subcommittee on Health and Human Resources, "The need for state funding for the use of atypical antipsychotic agents in severe mental illness."
12/1996	Invited oral testimony, House of Delegates of the Commonwealth of Virginia, Appropriations Committee, "The need for state funding for the use of atypical antipsychotic agents in severe mental illness."
05/1996	Guest, XL-102 radio, Richmond, Virginia, with Valerie Marsh, director of the Virginia Alliance for the Mentally Ill, "A discussion about serious mental illness"
01/1997	Oral and written testimony, General Assembly of the Commonwealth of Virginia, Hall-Gartlan Committee on Mental Health, "Findings on the cost-effectiveness of atypical antipsychotic agents in Virginia"
2000-2005	Advisory board member, Families for Depression Awareness (Waltham MA)
05/2007	Invited oral testimony, Georgia Legislature, Committee on Mental Health, regarding psychiatric advance directives, in collaboration with the Georgia Psychiatric Physicians Association.
08/2011	Interview, The Colbert Report, "A First-Rate Madness"
08/2011	Book reviews in the Wall Street Journal, New York Times, and Washington Post: "A First-Rate Madness"
2011-current	Multiple television (MSNBC, Fox) and radio (multiple National Public Radio and other stations) interviews nationwide about leadership and mood illness based on publication of "A First-Rate Madness"
10/2015	Invited consultant, Apple Inc headquarters, Mental health app advisor, Cupertino California

BIBLIOGRAPHY

Books

1. **Ghaemi SN.** Clinical Psychopharmacology: Principles and Practice. New York: Oxford University Press, 2019.
2. **Ghaemi SN.** On Depression: Diagnosis, Drugs and Despair in the Modern World. Baltimore: Johns Hopkins Press, 2013.
3. **Ghaemi SN.** A First-Rate Madness: Uncovering the Links Between Leadership and Mental Illness. New York: Penguin Press; 2011.
4. **Ghaemi SN.** A Clinician's Guide to Statistics and Epidemiology: Measuring Truth and Uncertainty. Cambridge UK: Cambridge University Press, 2009

5. **Ghaemi SN.** The rise and fall of the biopsychosocial model: Eclectic psychiatry examined. Baltimore: Johns Hopkins University Press; 2009.
6. **Ghaemi SN.** Mood Disorders: A Practical Guide. Baltimore: Lippincott, Williams, and Wilkins; 2003. 2nd edition 2007.
7. **Ghaemi SN.** The Concepts of Psychiatry: A pluralistic approach to the mind and mental illness. Baltimore: Johns Hopkins University Press; 2003, 2007.
8. El-Mallakh R, **Ghaemi SN** (editors). Bipolar Depression. Washington DC: American Psychiatric Press, 2006.
9. **Ghaemi SN** (editor). Polypharmacy in Psychiatry. New York: Marcel Dekker; 2002.

Original Articles

1. **Ghaemi SN, Stoll AL, Pope HG.** Lack of insight in bipolar disorder: the acute manic episode. *Journal of Nervous and Mental Disease* 1995;183:464-7.
2. **Ghaemi SN, Zarate C, Pillay SS, Popli A, Cole JO.** Is there a relationship between clozapine and obsessive-compulsive disorder? *Comprehensive Psychiatry* 1995;36:267-70.
3. **Ghaemi SN, Hebben N, Stoll AL, Pope HG.** Neuropsychological aspects of lack of insight in bipolar disorder. *Psychiatry Research* 1996;65:113-20.
2. **Ghaemi SN, Sachs GS, Baldassano CB, Truman CJ.** Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. *Canadian Journal of Psychiatry*, 1996;42:196-9
6. Fava M, Alpert J, Nierenberg AA, **Ghaemi SN**, O'Sullivan R, Tedlow J, Worthington J, Rosenbaum JF. Fluoxetine treatment of anger attacks: a replication study. *Annals of Clinical Psychiatry* 1996; 8:7-10.
8. Nierenberg AA, **Ghaemi SN**, Clancy K, Rosenbaum JF, Fava M. Cynicism, hostility, and suicidal ideation in depressed outpatients. *Journal of Nervous and Mental Disease* 1996;184:607-11.
11. **Ghaemi SN, Sachs GS, Baldassano CF, Truman CJ.** Insight in seasonal affective disorder. *Comprehensive Psychiatry*. 1997;38:345-8.
12. **Ghaemi SN, Sachs GS.** Long-term risperidone treatment in bipolar disorder: six month follow-up. *International Clinical Psychopharmacology*. 1997;12:333-8.
14. **Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK.** Cost-effectiveness of clozapine therapy for severe psychosis in Virginia. *Psychiatric Services*, 1998;49:829-30.
15. **Ghaemi SN, Katzow JJ, Desai SM, Goodwin FK.** Gabapentin treatment of mood disorders: a preliminary study. *Journal of Clinical Psychiatry*, 1998;59:426-9.
16. Davidoff SA, Forester, BP, **Ghaemi SN**, Bodkin JA. Effect of video self-observation on development of insight in psychotic disorders. *Journal of Nervous and Mental Disease*, 1998;186:697-700.
17. **Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin FK.** Is bipolar disorder still underdiagnosed? Are antidepressants underutilized? *Journal of Affective Disorders*, 1999;52:135-44.
18. **Ghaemi SN, Katzow JA.** The use of quetiapine in treatment-resistant bipolar disorder: a case series. *Annals of Clinical Psychiatry*, 1999;11:137-40.
19. Irizarry MC, **Ghaemi SN**, Lee-Cherry ER, Gomez-Isla T, Binetti G, Hyman BT, Growdon JH. Risperidone treatment of behavioral disturbances in outpatients with dementia. *Journal of Neuropsychiatry and Clinical Neurosciences*, 1999;11:336-42.

20. **Ghaemi SN**, Shields GS, Hegarty JH, Goodwin FK. Cholesterol in mood disorders: high or low? *Bipolar Disorders* 2000;6:287-94.
21. Sporn J, **Ghaemi SN**, Sambur MR, Rankin MA, Recht J, Sachs GS, Rosenbaum JF, Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: A retrospective chart review, *Annals of Clinical Psychiatry*, 2000;12:137-40.
22. **Ghaemi SN**, Lee-Cherry ER, Goodwin FK. Does olanzapine have antidepressant properties? *Bipolar Disorders* 2000;2:196-9.
23. Guille C, Sachs GS, **Ghaemi SN**. A naturalistic comparison of atypical antipsychotic agents in bipolar disorder. *Journal of Clinical Psychiatry*, 2000;61:638-42.
24. **Ghaemi SN**, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants. *Journal of Clinical Psychiatry*, 2000;61: 804-8.
25. **Ghaemi SN**, Boiman EE, Goodwin FK. Insight and outcome in bipolar, unipolar, and anxiety disorders. *Comprehensive Psychiatry*, 2000;41:167-71.
26. **Ghaemi SN**, Goodwin FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. *Journal of Affective Disorders* 2001;65:167-71.
27. **Ghaemi SN**, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. *Journal of Affective Disorders* 2001;65,281-7.
28. **Ghaemi SN**, Kirkwood CK, Sambur MR, Ko JY, Howden KL, Duong Q-V, Goodwin FK. Economic outcomes of risperidone in comparison to typical neuroleptic agents for treatment-resistant psychosis: a community-based study. *Journal of Pharmacy Technology* 2001;17:273-8.
29. **Ghaemi SN**, Manwani SG, Katzow JJ, Ko JY, Goodwin FK. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. *Annals of Clinical Psychiatry* 2001;13:185-9.
30. **Ghaemi SN**, Ko JY, Katzow JJ. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. *Bipolar Disorders* 2002;4:70-4.
31. Sachs GS, Grossman F, **Ghaemi SN**, Okimoto A, Bowden CL. Risperidone plus mood stabilizer versus placebo plus mood stabilizer for acute mania of bipolar disorder: a double-blind comparison of efficacy and safety. *American Journal of Psychiatry* 2002;159:1146-54.
32. **Ghaemi SN**, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ. Oxcarbazepine treatment of refractory bipolar disorder. *Journal of Clinical Psychiatry* 2003; 8:943-5
33. **Ghaemi SN**, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar vs unipolar depression. *American Journal of Psychiatry*, 2004;161: 163-166. Henry CA, Zamvil LS, Lam C, Rosenquist KJ, **Ghaemi SN**. Long-term outcome with divalproex in children and adolescents with bipolar disorder. *Journal of Child and Adolescent Psychopharmacology*, 2003; 13:523-530.
34. Miller CJ, Klugman J, Berv DA, Rosenquist KJ, **Ghaemi SN**. Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar disorder. *Journal of Affective Disorders*, 2004;8:167-71.
35. **Ghaemi SN**, Hsu DJ, Rosenquist KJ, Katzow JJ, Goodwin FK. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. *Annals of Clinical Psychiatry*, 2004;16:69-73.

36. Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, **Ghaemi SN**, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. *British Journal of Psychiatry* 2004; 184: 337-345.
37. Baldassano CF, **Ghaemi SN**, Chang A, Lyman A, Lipari M. Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review. *Bipolar Disorders*. 2004, 6:432-434.
38. **Ghaemi SN**, Hsu DJ, Ko JY, Baldassano CF, Kontos NJ, Goodwin FK. Bipolar spectrum disorder: a pilot study. *Psychopathology*. 2004;37:222-6.
39. **Ghaemi SN**, Miller CJ, Rosenquist KJ, Pies R. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. *J Affect Disord*. 2005;84:273-7.
40. Revicki DA, Hanlon J, Martin S, Gyulai L, **Ghaemi SN**, Lynch F, Mannix S, Kleinman L. Patient-based utilities for bipolar disorder-related health states. *Journal of Affective Disorders*, 2005; 87:203-210.
41. Soldani F, **Ghaemi SN**, Baldessarini RJ. Research reports on treatments for bipolar disorder: preliminary assessment of methodological quality. *Acta Psychiatr Scand*. 2005 Jul;112(1):72-4
42. Pae CU, **Ghaemi SN**, Kim TS, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. *Psychopharmacology*. 2005; 20: 327-30.
43. Baldassano CF, Marangell LB, Gyulai L, **Ghaemi SN**, Joffe H, Kim DR, Sagduyu K, Truman CJ, Wisniewski SR, Sachs GS, Cohen LS. Gender differences in bipolar disorder: retrospective data from the first 500 participants. *Bipolar Disorders* 2005; 7:465-470.
44. **Ghaemi SN**, Rosenquist KJ, Pardo TB, Goodwin FK. Extrapyramidal side effects with atypical neuroleptic agents in bipolar disorder. *Progress Neuropsychopharm Biol Psychiatry*, 2006;30:209-13.
45. Pae CU, Kim TS, Lee KU, Kim JJ, Patkar AA, Masand PS, **Ghaemi SN**, Lee CU, Lee SJ, Lee C, Paik IH: Clinical variables associated with early administration of antipsychotics in bipolar mania. *Prog Neuropsychopharmacol Biol Psychiatry* 2006;30:151-4
46. Albanese MJ, Clodfelter RC, Pardo TB, **Ghaemi SN**. Misdiagnosis of bipolar disorder in men with substance use disorder. *Journal of Dual Diagnosis*, 2006, 12: 124-127.
47. Pollack MH, Simon NM, Fagiolini A, Pitman R, McNally RJ, Nierenberg AA, Miyahara S, Sachs G, Perlman C, **Ghaemi SN**, Thase ME, Otto MW. Persistent PTSD in bipolar patients following September 11th. *Journal of Clinical Psychiatry*, 2006, 67:394-9.
48. **Ghaemi SN**, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. *Psychiatric Services*, 2006, 57:660-665.
49. **Ghaemi SN**, Zablotsky B, Filkowski MM, Dunn RT, Pardo TB, Isenstein E, Baldassano CF. An open prospective study of zonisamine in bipolar depression. *Journal of Clinical Psychopharmacology*, 2006, 26: 385-388.

50. **Ghaemi SN**, Schrauwen E, Klugman J, Berv DA, Shirzadi AA, Pardo TB, Goodwin FK. Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. *Journal of Psychiatric Practice*, 2006, 12: 300-305.
51. Manwani SG, Pardo TB, Albanese MJ, Zablotsky B, Goodwin FK, **Ghaemi SN**. Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. *J Clin Psychiatry*. 2006;67:1341-5.
52. Ernst CL, Bird SA, Goldberg JF, **Ghaemi SN**. The prescription of psychotropic medications for patients discharged from a psychiatric emergency service. *J Clin Psychiatry*. 2006;67:720-6.
53. Pae CU, **Ghaemi SN**, Patkar A, Chae JH, Bahk WM, Jun TY, Masand P. Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006;30:1322-5.
54. Schrauwen E, **Ghaemi SN**. Galantamine treatment of cognitive impairment in bipolar disorder: four cases. *Bipolar Disord*. 2006;8:196-9.
55. **Ghaemi SN**, Shirzadi AA, Klugman J, Berv DA, Pardo TB, Filkowski MM. Is Zonisamide an effective adjunctive treatment for bipolar disorder? *Journal of Affective Disorders*, 2008 Jan;105(1-3):311-4.
56. **Ghaemi SN**, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley M, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT. Divalproex in the treatment of acute bipolar depression: A preliminary double-blind, randomized, placebo-controlled pilot study. *Journal of Clinical Psychiatry*, 2007 Dec;68(12):1840-4.
57. Truman CJ, Goldberg JF, **Ghaemi SN**, Baldassano CF, Wisniewski SR, Dennehy EB, Thase ME, Sachs GS. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *J Clin Psychiatry*. 2007 Oct;68(10):1472-9
58. Goldberg JF, Perlis RH, **Ghaemi SN**, Calabrese JR, Bowden CL, Wisniewski S, Miklowitz DJ, Sachs GS, Thase ME. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. *Am J Psychiatry*. 2007 Sep;164(9):1348-55.
59. Goldberg JF, Kelley M, Rosenquist KJ, Hsu DJ, Filkowski MM, **Ghaemi SN**. Effectiveness of quetiapine in rapid-cycling bipolar disorder: a preliminary open-label trial. *Journal of Affective Disorders, J Affect Disord*. 2008 Jan;105(1-3):305-10.
60. Dunn RT, Stan VA, Chriki LS, Filkowski MM, **Ghaemi SN**. A prospective, open-label study of aripiprazole mono- and adjunctive treatment in acute bipolar depression. *J Affect Disord*. 2008 Feb 11 issue.
61. Goldberg JF, Brooks JO, Kurita K, Hoblyn JC, **Ghaemi SN**, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: Findings from the STEP-BD. *J Clin Psychiatry*. 2009
62. Shabani A, Koohi-Habibi L, Nojomi M, Chimeh N, **Ghaemi SN**, Soleimani N. The Persian bipolar spectrum diagnostic scale and mood disorder questionnaire in screening the patients with bipolar disorder. *Arch Iran Med*. 2009 Jan;12(1):41-7.
63. Wingo AP, **Ghaemi SN**. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients *Psychopharmacol Bull*. 2008;41(4):37-47.

64. El-Mallakh RS, **Ghaemi SN**, et al. Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. *J Affect Disord*. 2008 Dec;111(2-3):372-7.
65. **Ghaemi SN**, Gilmer WS, Dunn RT, Hanlon RE, Kemp DE, Bauer AD, Chriki L, Filkowi MM, Harvey PD. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. *J Clin Psychopharmacol*. 2009 Jun;29(3):291-5.
66. **Ghaemi SN**, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs GS, Goodwin FK, Baldessarini RJ. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. *J Clin Psychiatry*. 2010 Apr;71(4):372-80.
67. Chilakamarri JK, Filkowski MM, **Ghaemi SN**. Misdiagnosis of bipolar disorder in children and adolescents: a comparison with ADHD and major depressive disorder. *Ann Clin Psychiatry*. 2011 Feb;23(1):25-9.
68. Strejilevich SA, Martino DJ, Marengo E, Igoa A, Fassi G, Whitham EA, **Ghaemi SN**. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. *Annals of Clinical Psychiatry*, 2011; 23(3):186-92.
69. Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, **Ghaemi SN**. Predictors of Response to Ziprasidone: Results from a 6-Week Randomized Double-Blind, Placebo-Controlled Trial for Acute Depressive Mixed State. *Pharmacopsychiatry* 2012; 45: 152-155
70. Patkar A, Gilmer W, Pae CU, Vöhringer PA, Ziffra M, Pirok E, Mulligan M, Filkowski MM, Whitham EA, Holtzman NS, Thommi SB, Logvinenko T, Loebel A, Masand P, **Ghaemi SN**. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. *PLoS One*, 2012; 7(4):e34757.
71. Pae CU, Vöhringer PA, Holtzman NS, Thommi SB, Patkar A, Gilmer W, **Ghaemi SN**. Mixed depression: a study of its phenomenology and relation to treatment response. *Journal of Affective Disorders*, 2012; 136(3):1059-61.
72. Vöhringer PA, Whitham EA, Thommi SB, Holtzman NS, Khrad H, **Ghaemi SN**. Affective temperaments in clinical practice: a validation study in mood disorders. *Journal of Affective Disorders*, 2012; 136(3):577-80.
73. Pae CU, Vöhringer PA, Holtzman NS, Thommi SB, Patkar A, Gilmer W, **Ghaemi SN**. Mixed depression: a study of its phenomenology and relation to treatment response. *Journal of Affective Disorders*, 2012; 136(3):1059-61.
74. Sani G, Kotzalidis GD, Vöhringer P, Pucci D, Simonetti A, Manfredi G, Savoia V, Tamorri SM, Mazzarini L, Pacchiarotti I, Telesforo CL, Ferracuti S, Brugnoli R, Ambrosi E, Caloro M, Del Casale A, Koukopoulos AE, Vergne DE, Girardi P, **Ghaemi SN**. Effectiveness of Short-Term Olanzapine in Patients With Bipolar-I Disorder, With or Without Comorbidity With Substance Use Disorder. *J Clin Psychopharmacol*. 2013 Apr; 33(2):231-5.
75. Vöhringer PA, Jimenez MI, Igor MA, Fores GA, Correa MO, Sullivan MC, Holtzman NS, Whitham EA, Barroilhet SA, Alvear K, Logvinenko T, Kent DM, **Ghaemi SN**. Detecting mood disorder in resource-limited primary care settings: comparison of a self-administered screening tool to general practitioner assessment. *J Med Screen*. 2013;20(3):118-24.
76. Vöhringer PA, Jimenez MI, Igor MA, Forés GA, Correa MO, Sullivan MC, Holtzman NS, Whitham EA, Barroilhet SA, Alvear K, Logvinenko T, Kent DM, **Ghaemi SN**. A

- clinical predictive score for mood disorder risk in low-income primary care settings. *J Affect Disord.* 2013 Dec;151(3):1125-31.
77. Sani G, Vöhringer PA, Napoletano F, Holtzman NS, Dalley S, Girardi P, **Ghaemi SN**, Koukopoulos A. Koukopoulos' diagnostic criteria for mixed depression: A validation study. *J Affect Disord.* 2014 Aug;164:14-8
 78. Mauer S, Alahmari R, Vöhringer PA, Vergne DE, Lövdahl H, Correa E, Patkar A, Pae C, Strejilevich S, Dalley S, **Ghaemi SN**. International prescribing patterns for mood illness: the International Mood Network (IMN). *J Affect Disord.* 2014;167:136-9.
 79. Sani G, Napoletano F, Vöhringer PA, Sullivan M, Simonetti A, Koukopoulos A, Danese E, Girardi P, **Ghaemi N**. Mixed depression: Clinical features and predictors of its onset associated with antidepressant use. *Psychother Psychosom.* 2014;83(4):213-21
 80. Patkar AA, Pae CU, Vöhringer PA, Mauer S, Narasimhan M, Dalley S, Loebel A, Masand PS, **Ghaemi SN**. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. *J Clin Psychopharmacol.* 2015 Jun;35(3):319-23.
 81. Vohringer PA, Ostacher MJ, El-Mallakh RS, Holtzman NS, Thommi SB, Whitham EA, Sullivan MC, Baldassano CF, Goodwin FK, Baldessarini RJ, **Ghaemi SN**. Antidepressants in type II versus type I bipolar depression: A randomized discontinuation trial. *J Clin Psychopharmacol* 2015, 35: 605-608.
 82. Amerio A, Tonna M, Odone A, Stubbs B, **Ghaemi SN**. Heredity in comorbid bipolar disorder and obsessive-compulsive disorder patients. *Shanghai Arch Psychiatry* 2015 Oct; 27 (5): 307-310.
 83. El-Mallakh RS, Vöhringer PA, Ostacher MM, Baldassano CF, Holtzman NS, Whitham EA, Thommi SB, Goodwin FK, **Ghaemi SN**. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. *J Affect Disord.* 2015 Sep 15;184:318-2
 84. Amerio A, Tonna M, Odone A, Stubbs B, **Ghaemi SN**. Course of illness in comorbid bipolar disorder and obsessive-compulsive disorder patients. *Asian J Psychiatr.* 2016 Apr; 20:12-14.
 85. Amerio A, Tonna M, Odone A, Stubbs B, **Ghaemi SN**. Psychiatric comorbidities in comorbid bipolar disorder and obsessive-compulsive disorder patients. *Asian J Psychiatr* 2016 Jun; 21: 23-4.
 86. Vöhringer PA, Barroilhet SA, Alvear K, Medina S, Espinosa C, Alexandrovich K, Riumallo P, Leiva F, Hurtado ME, Cabrera J, Sullivan M, Holtzman N, **Ghaemi SN**. The International Mood Network (IMN) Nosology Project: differentiating borderline personality from bipolar illness. *Acta Psychiatr Scand.* 2016 Dec;134(6):504-510.
 87. Sani G, Vöhringer PA, Barroilhet SA, Koukopoulos AE, **Ghaemi SN**. The Koukopoulos Mixed Depression Rating Scale (KMDRS): An International Mood Network (IMN) validation study of a new mixed mood rating scale. *J Affect Disord.* 2018; 232:9-16
 88. Vöhringer PA, Sani G, Barroilhet SA, Mao Y, **Ghaemi SN**. Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale. *J Clin Psychopharmacol.* 2020;40:491-494.

89. Pottel J, Armstrong D, Zou L, Fekete A, Huang XP, Torosyan H, Bednarczyk D, Whitebread S, Bhatarai B, Liang G, Jin H, **Ghaemi SN**, Slocum S, Lukacs KV, Irwin JJ, Berg EL, Giacomini KM, Roth BL, Shoichet BK, Urban L. The activities of drug inactive ingredients on biological targets. *Science*. 2020;369:403-413
90. **Ghaemi SN**, Whitham EA, Vohringer PA, Barroilhet SA, Amerio A, Sverdlov O, Patkar AA. Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial. *J Clin Psychiatry*. 2021;82(1):19m13136
91. Sretavan Wong K, Migó M, Dougherty DD, **Ghaemi SN**. Neural correlates of citalopram and placebo response in acute bipolar depression: A randomized trial. *J Psychiatr Res*. 2021;138:463-466
92. **Ghaemi SN**, Sverdlov O, van Dam J, Campellone T, Gerwien R. A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial. *JMIR Form Res*. 2022 Mar 28;6(3):e29154

Reviews and conceptual articles (peer-reviewed)

1. **Ghaemi SN**, Pope HG. Lack of insight in psychotic and affective disorders: a review of the empirical literature. *Harvard Review of Psychiatry* 1994;2:22-33.
2. **Ghaemi SN**, Oepen GO. Mind/brain theories in clinical psychiatry. *Integrative Psychiatry* 1994;10:52-7.
3. Baldassano CF, Truman CJ, Nierenberg AA, **Ghaemi SN**, Sachs GS. Akathisia: a review and case report following paroxetine treatment. *Comprehensive Psychiatry* 1996;37:122-4.
4. Melton SA, Kirkwood CK, **Ghaemi SN**. Pharmacotherapy of HIV dementia. *Annals of Pharmacotherapy* 1997;31:457-73.
5. Goodwin FK, **Ghaemi SN**. Prospects for a scientific psychiatry. *Acta Neuropsychiatrica* 1997;9:49-51.
6. **Ghaemi SN**. Guest Editor. Lack of insight in psychiatric disorders. *Psychiatric Annals*, Volume 27, No.12, December 1997.
7. **Ghaemi SN**. Insight and psychiatric disorders: a review of the literature, with a focus on its clinical relevance for bipolar disorder. *Psychiatric Annals* 1997;27:782-90.
8. Goodwin FK, **Ghaemi SN**. Understanding manic-depressive illness. *Archives of General Psychiatry*. 1998;55:23-5.
9. **Ghaemi SN**, Boiman EE, Goodwin FK. Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. *Biological Psychiatry*, 1999;45:137-44.
10. **Ghaemi SN**. Understanding delusions: an empirical approach. *Philosophy, Psychiatry, and Psychology*, 1999;6:21-4.
11. **Ghaemi SN**, Goodwin FK. The use of atypical antipsychotic agents in bipolar and schizoaffective disorders: a critical review. *Journal of Clinical Psychopharmacology*, 1999;19:354-61.
12. Goodwin FK, **Ghaemi SN**. Guest Editors. Time bomb: Bipolar disorder and suicide. *Primary Psychiatry*, September 1999, Volume 6, No. 9.
13. Goodwin FK, **Ghaemi SN**. The impact of mood stabilizers on suicide in bipolar disorder: a comparative analysis. *Primary Psychiatry*, 1999;6:61-70.

14. Goodwin FK, **Ghaemi SN**. Bipolar disorder: the state of the art. *Dialogues in Clinical Neuroscience*, 1999;1:41-51.
15. **Ghaemi SN**. Performative statements and the will. *American Journal of Psychotherapy*, 1999,53:483-94.
16. **Ghaemi SN**. Depression: Insight, illusion, and psychopharmacological Calvinism. *Philosophy, Psychiatry, and Psychology* 1999;6:287-94.
17. **Ghaemi SN**, Goodwin FK. What is to be done? Current controversies in the diagnosis and treatment of bipolar disorder. *World Journal of Biological Psychiatry* 2000;1:65-74.
18. **Ghaemi SN**, Gaughan SA. The use of novel anticonvulsants in bipolar disorder: a review of the empirical literature. *Harvard Review of Psychiatry* 2000,8:1-7
19. Glick RL, **Ghaemi SN**. The emergency treatment of depression complicated by psychosis or agitation. *Journal of Clinical Psychiatry supplement* 2000;61:804-8.
20. **Ghaemi SN**. New treatments for bipolar disorder: the role of atypical neuroleptic agents. *Journal of Clinical Psychiatry supplement* 2000;61(suppl 14):33-42
21. Sachs GS, Koslow CL, **Ghaemi SN**. The treatment of bipolar depression. *Bipolar Disorders* 2000;2:256-60.
22. **Ghaemi SN**. Bipolar disorder and antidepressants: an ongoing controversy. *Primary Psychiatry* 2001;8:28-34.
23. **Ghaemi SN**. Rediscovering existential psychotherapy: the contribution of Ludwig Binswanger. *American Journal of Psychotherapy* 2001;55:51-64.
24. **Ghaemi SN**, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. *Journal of Clinical Psychiatry* 2001;62:565-9.
25. **Ghaemi SN**, On defining 'mood stabilizer'. *Bipolar Disorders* 2001;3:154-8.
26. **Ghaemi SN**, Ko JY, Goodwin FJ. The bipolar spectrum and the antidepressant view of the world. *Journal of Psychiatric Practice* 2001;7:287-97.
27. **Ghaemi SN**, Ko JY, Goodwin FK. "Cade's Disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. *Canadian Journal of Psychiatry* 2002;47:125-34.
28. **Ghaemi SN**, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. *Primary Psychiatry* 2002;9:55-9.
29. Baldessarini RJ, **Ghaemi SN**, Viguera AC. Tolerance in antidepressant treatment. *Psychotherapy and Psychosomatics* 2002;71:177-9.
30. **Ghaemi SN**, Goodwin FK. Co-guest editors. *Bipolar Disorders*. Special issue on antidepressant use in bipolar disorder, December, 2003. Vol 5, Issue 6.
31. Katzow JJ, Hsu DJ, **Ghaemi SN**. The bipolar spectrum: a clinical perspective. *Bipolar Disorders*. 2003, 5:436-42.
32. **Ghaemi SN**, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. *Bipolar Disorders* 2003; 5:421-33.
33. **Ghaemi SN**, Goodwin FK. Guest Editors. Antidepressants and the bipolar spectrum. *Bipolar Disorders* 2003; 5(6)
34. **Ghaemi SN**, Soldani F, Hsu DJ. Evidence-based pharmacotherapy of bipolar disorder. *Int J Neuropsychopharmacol*. 2003 Sep;6(3):303-8.
35. Goodwin FK, **Ghaemi SN**. The course of bipolar disorder and the nature of agitated depression. *Am J Psychiatry* 2003;160(12):2077-9.

36. Henry CA, **Ghaemi SN**. Insight in psychosis: A systematic review of treatment interventions. *Psychopathology*, 2004, Jul-Aug;37(4):194-9.
37. **Ghaemi SN**, Rosenquist KJ. Is insight in mania state-dependent?: a meta-analysis. *J Nerv Ment Dis*. 2004 Nov;192(11):771-5.
38. **Ghaemi SN**, Pardo TB, Hsu DJ. Strategies for preventing the recurrence in bipolar disorder. *J Clin Psychiatry*. 2004;65 Suppl 10:16-23.
39. **Ghaemi SN**, Soldani F. Lamotrigine and lithium are effective maintenance treatments in recently depressed people with bipolar I disorder. *Evid Based Ment Health*. 2004 May;7:48.
40. Soldani F, **Ghaemi SN**, Baldessarini RJ. Research methods in psychiatric treatment studies. Critique and proposals. *Acta Psychiatr Scand*. 2005;112:1-3.
41. Havens LL, **Ghaemi SN**. Existential despair and bipolar disorder: The therapeutic alliance as a mood stabilizer. *American Journal of Psychotherapy*, 2005;59:137-47.
42. Smith DJ, **Ghaemi SN**. Hypomania in clinical practice. *Advances in Psychiatric Treatment*. 2006; 12: 110-120
43. Phelps J, **Ghaemi SN**. Improving the diagnosis of bipolar disorder: Predictive value of screening tests. *Journal of Affective Disorders*, 2006, 92: 141-48.
44. **Ghaemi SN**. Paradigms of psychiatry: eclecticism and its discontents. *Current Opinion in Psychiatry*, 2006, 19: 619-624.
45. **Ghaemi SN**. Hippocratic Psychopharmacology for Bipolar Disorder, *Psychiatry MMC*; 2006, 3:30-39.
46. **Ghaemi SN**. Hippocrates and Prozac. *Primary Psychiatry* 2006; 13:51-58
47. Shirzadi AA, **Ghaemi SN**. Side effects of atypical antipsychotics: Extrapyramidal symptoms and the metabolic syndrome. *Harvard Review of Psychiatry*, 2006, 14: 152-64.
48. **Ghaemi SN**. Feeling and time: The phenomenology of mood disorders, depressive realism, and existential psychotherapy. *Schizophrenia Bulletin*, 2007, 33:122-30.
49. **Ghaemi SN**, Baldessarini RJ. The manic-depressive spectrum and mood stabilization: Kraepelin's ghost. *Psychotherapy and Psychosomatics* 2007; 76:65-69
50. **Ghaemi SN**. Existence and pluralism: The rediscovery of Karl Jaspers. *Psychopathology*, 2007;40:75-82
51. **Ghaemi SN**, Martin A. Defining the boundaries of childhood bipolar disorder. *Am J Psychiatry*. 2007;164:185-8
52. Wingo AP, **Ghaemi SN**. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. *J Clin Psychiatry*. 2007 Nov;68(11):1776-84.
53. **Ghaemi SN**, Goodwin FK. The ethics of clinical innovation in psychopharmacology: Challenging traditional bioethics. *Philos Ethics Humanit Med*. 2007 Nov 8;2(1):26
54. **Ghaemi SN**. Pluralism in psychiatry: Karl Jaspers on science. *Philosophy, Psychiatry, Psychology*, 2007, in press.
55. **Ghaemi SN**, Bauer M. Guest Editors: *Bipolar Disorders*, Special issue on the Recommendations of the Diagnostic Task Force of the International Society for Bipolar Disorders. February 2008.
56. Smith, DJ, **Ghaemi SN**, Craddock N. The broad clinical spectrum of bipolar disorder: implications for research and practice. *J Psychopharmacol*. 2008 Jun;22(4):397-400
57. **Ghaemi SN**. Toward a Hippocratic psychopharmacology. *Can J Psychiatry*. 2008 Mar;53(3):189-96.

58. **Ghaemi SN.** All mixed up: on the absence of diagnostic guidelines for mixed states in the ISBD Diagnostic Guidelines Task Force Report. *Bipolar Disord.* 2008 Feb;10(1 Pt 2):129-130
59. **Ghaemi SN et al.** Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. *Bipolar Disord.* 2008 Feb;10(1 Pt 2):117-28.
60. **Ghaemi SN.** Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? *Am J Psychiatry.* 2008 Mar;165(3):300-2.
61. Kendler KS, Appelbaum PS, Bell CC, Fulford KW, **Ghaemi SN**, Schaffner KF, Waterman GS, First MB, Sadler JZ. Issues for DSM-V: DSM-V should include a conceptual issues work group. *Am J Psychiatry.* 2008 Feb;165(2):174-5.
62. **Ghaemi SN**, Shirzadi AA, Filkowski MM. Publication bias and negative studies: The case of lamotrigine in bipolar disorder. *Medscape Journal of Medicine,* 2008;10(9):211. <http://www.medscape.com/viewarticle/579046>
63. Koukopoulos A, **Ghaemi SN.** The primacy of mania: A reconsideration of mood disorders. *Eur Psychiatry.* 2008 Sep 11
64. **Ghaemi SN**, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. *Acta Psychiatr Scand.* 2008;118(5):347-56
66. **Ghaemi SN.** The case for, and against, evidence-based psychiatry. *Acta Psychiatr Scand.* 2009;119:349-251
67. **Ghaemi SN.** Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. *Bipolar Disorder.* 2008 Dec: 10(8): 957-68.
68. **Ghaemi SN.** Nosologomania: DSM & Karl Jaspers' critique of Kraepelin. *Philos Ethics Humanit Med.* 2009 Jul 23;4:10.
69. **Ghaemi SN.** The failure to know what isn't known: negative publication bias with lamotrigine and a glimpse inside peer review. *Evid Based Ment Health.* 2009 Aug;12(3):65-8.
70. Smith DJ, **Ghaemi N.** Is underdiagnosis the main pitfall when diagnosing bipolar disorder? Yes. *BMJ.* 2010 Feb 22;340:c854.
71. **Ghaemi SN**, Thommi SB. Death by confounding: bias and mortality. *Int J Clin Pract,* 2010; 64: 1009-14.
72. Goodwin FK, **Ghaemi, SN.** The Conundrum of Schizoaffective Disorder: A Review of the Literature. *Psychiatric Annals;* March 2010; 40(3): 168-71.
73. Daray FM, Thommi SB, **Ghaemi SN.** The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. *Bipolar Disord.* 2010 Nov;12(7):702-6.
74. Galvez JF, Thommi S, **Ghaemi SN.** Positive aspects of mental illness: a review in bipolar disorder. *J Affect Disord.* 2011 Feb; 128(3): 185-90.
75. Vergne DE, Whitham EA, Barriolhet S, Fradkin Y, **Ghaemi SN.** Adult ADHD and amphetamines: a new paradigm. *Bipolar Disorders* 2011; 13: 583–586.
76. Malhi GS, Chengappac RKN, Gershond S, and **Ghaemi, SN.** Atypical mood stabilizers: a new role for neuroleptics? *Bipolar Disorders* 2011; 13: 583–586.
77. **Ghaemi SN.** The biopsychosocial model in psychiatry: A critique. *Existenz.* Spring 2011, Vol 6, No. 1. Accessed at: <https://existenz.us/volumes/Vol.6-1Ghaemi.html>
78. Stone K, Whitham EA, **Ghaemi SN.** A comparison of psychiatry and internal medicine: a bibliometric study. *Academic Psychiatry.* 2012 36(2):129-32.

79. **Ghaemi SN**. Antidepressants in bipolar depression: the clinical debate. *The Australian and New Zealand Journal of Psychiatry*, 2012; 46(4):298-301.
80. Vöhringer PA, **Ghaemi SN**. Solving the antidepressant efficacy question: effect sizes in major depressive disorder. *Clinical Therapeutics*, 2011; 33(12):B49-61.
81. Malhi GS, Chengappa KN, Gershon S, **Ghaemi SN**. Atypical mood stabilizers: a new role for neuroleptics? *Bipolar Disorders*, 2011; 13(7-8):583-6.
82. **Ghaemi SN**, Vöhringer PA. The heterogeneity of depression: an old debate renewed. *Acta Psychiatrica Scandinavica*, 2011; 124(6):497.
83. Goodwin FK, Whitham EA, **Ghaemi SN**. Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? *CNS Drugs*, 2011; 25(10):819-27.
84. **Ghaemi SN**, Vöhringer PA, Vergne DE. The varieties of depressive experience: diagnosing mood disorders. *Psychiatric Clinics of North America*, 2012; 35(1):73-86.
85. Omrani A, Holtzman NS, Akiskal HS, **Ghaemi SN**. Ibn Imran's 10th century Treatise on Melancholy. *Journal of Affective Disorders*, 2012; 141(2-3):116-9.
86. Phelps J, **Ghaemi SN**. The mistaken claim of bipolar 'overdiagnosis': solving the false positives problem for DSM-5/ICD-11. *Acta Psychiatrica Scandinavica*, 2012; 126(6):395-401.
87. **Ghaemi SN**, Vöhringer PA, Whitham EA. Antidepressants from a public health perspective: re-examining effectiveness, suicide, and carcinogenicity. *Acta Psychiatrica Scandinavica*, 2013; 127(2):89-93.
88. **Ghaemi SN**. Against 'pragmatism' in DSM/ICD: a commentary on prodromal psychosis. *Acta Psychiatrica Scandinavica*. 2013; 127(3):253.
89. Phillips J, Frances A, Cerullo MA, Chardavoyne J, Decker HS, First MB, **Ghaemi N**, Greenberg G, Hinderliter AC, Kinghorn WA, LoBello SG, Martin EB, Mishara AL, Paris J, Pierre JM, Pies RW, Pincus HA, Porter D, Pouncey C, Schwartz MA, Szasz T, Wakefield JC, Waterman GS, Whooley O, Zachar P. The six most essential questions in psychiatric diagnosis: a pluralogue **parts 1-4**. *Philosophy, Ethics, and Humanities in Medicine*, 2012.
90. **Ghaemi SN**. Bipolar spectrum: A review of the concept and a vision for the future. *Psychiatry Investigation*, 2013; 10(3): 218-24.
91. Vöhringer PA, Barroilhet SA, Amerio A, Reale ML, Alvear K, Vergne D, **Ghaemi SN**. Cognitive impairment in bipolar disorder and schizophrenia: a systematic review. *Frontiers of Psychiatry*. 2013 Aug 8;4:87.
92. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, **Ghaemi SN**, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. *Am J Psychiatry*. 2013 Nov 1;170(11):1249-62.

93. **Ghaemi SN.** Postmodern medicine: An analysis of the pharmaceutical industry and its critics. *Perspectives in Biology and Medicine*, 2013; 56 (2): 223-35.
94. **Ghaemi SN.** Psychopathology for what purpose? *Acta Psychiatrica Scandinavica*, 2014; 129: 78-9.
95. **Ghaemi SN.** The ‘pragmatic’ secret of DSM revisions. *Aust N Z J Psychiatry*. 2014 Feb;48(2):196-7
96. **Ghaemi SN.** DSM-5 and the miracle that never happens. *Acta Psychiatr Scand*. 2014 Jun;129(6):410-2
97. **Ghaemi SN, Dalley S, Catania C, Barroilhet S.** Bipolar or borderline: A clinical overview. *Acta Psychiatr Scand*. 2014 Aug;130(2):99-108
98. **Ghaemi SN, Dalley S.** The bipolar spectrum: Conceptions and misconceptions. *Australian and New Zealand Journal of Psychiatry*, 48: 314-324, 2014.
99. Amerio A, Odone A, Liapis CC, **Ghaemi SN.** Diagnostic validity of comorbid obsessive-compulsive disorder and bipolar disorder: A systematic review, *Acta Psychiatrica Scandinavica*, 2014 May;129(5):343-58.
100. Amerio A, Odone A, Marchesi C, **Ghaemi SN.** Treatment of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. *J Affect Disord*. 2014 Sep;166:258-63.
101. Mauer S, Verge D, **Ghaemi SN.** Standard and low-dose lithium: A systematic review of dementia prevention and other behavioral benefits. *Australian and New Zealand Journal of Psychiatry*, 2014 Sep;48(9):809-18.
102. **Amerio A, Gálvez JF, Odone A, Dalley SA, Ghaemi SN.** Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration-required preclinical in vivo studies. *Aust N Z J Psychiatry*. 2015 Apr 27.
103. **Ghaemi SN.** A new nomenclature for psychotropic drugs. *J Clin Psychopharmacol* 2015 May 27.
104. Amerio A, Stubbs B, Odone A, Tonna M, Marchesi C, **Ghaemi SN** The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review and meta-analysis. *J Affect Disord*. 2015 Nov 1;186:99-109.
105. **Tonna M, Amerio A, Odone A, Stubbs B, Ghaemi SN.** Comorbid bipolar disorder and obsessive compulsive disorder: Which came first? *Aust N Z J Psychiatry* 2015, 50: 695-698.
106. McGirr A, Vöhringer PA, **Ghaemi SN**, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabilizer or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomized placebo-controlled trials. *Lancet Psychiatry*. 2016; 3: 1138-1146.
107. **Ghaemi SN, Vohringer PA.** Athanasios Koukopoulos’ psychiatry: The primacy of mania and the limits of antidepressants. *Curr Neuropharmacol*. 2017;15:402-408.
108. **Ghaemi SN, Selker HP.** Maintenance efficacy designs in psychiatry: Randomized discontinuation trials - enriched but not better. *J Clin Transl Sci*. 2017 Jun;1(3):198-204
109. Amerio A, Ossola P, Scagnelli F, Odone A, Allinovi M, Cavalli A, Iacopelli J, Tonna M, Marchesi C, **Ghaemi SN.** Safety and efficacy of lithium in children and adolescents: A systematic review in bipolar illness. *Eur Psychiatry*. 2018 Oct;54:85-97

110. **Ghaemi SN**, Glick ID, Ellison JM. A Commentary on Existential Psychopharmacologic Clinical Practice: Advocating a Humanistic Approach to the "Med Check". *J Clin Psychiatry*. 2018;79(4).
111. Amerio A, Odone A, **Ghaemi SN**. Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. *J Affect Disord*. 2019;249:15-19
112. Amerio A, Maina G, **Ghaemi SN**. Updates in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. *J Affect Disord*. 2019;256:433-44
113. **Ghaemi SN**. Digital depression: A new disease of the millennium? *Acta Psychiatr Scand*. 2020;141:356-361.
114. Barroilhet SA, **Ghaemi SN**. Psychopathology of Mixed States. *Psychiatr Clin North Am*. 2020;43:27-46
115. Huang H, Huang H, Spottswood M, **Ghaemi SN**. Approach to Evaluating and Managing Adult Attention-Deficit/Hyperactivity Disorder in Primary Care. *Harv Rev Psychiatry*. 2020;28:100-106
116. **Ghaemi SN**. Aristotle on manic-depressive illness and greatness. *Bipolar Disord*. 2020;22:633-63
117. Barroilhet SA, **Ghaemi SN**. When and how to use lithium. *Acta Psychiatr Scand*. 2020;142:161-172.
118. **Ghaemi SN**. Using Psychiatric Rating Scales in Clinical Trials: A Proposal. *J Clin Psychopharmacol*. 2020;40:433-435
119. Amerio A, Odone A, Marzano L, Costanza A, Aguglia A, Serafini G, Signorelli C, **Ghaemi SN**, Amore M. Covid-19: The last call for telepsychiatry. *Acta Biomed*. 2020 Jul 28;91(3)
120. Costantini L, Pasquarella C, Odone A, Colucci ME, Costanza A, Serafini G, Aguglia A, Belvederi Murri M, Brakoulias V, Amore M, **Ghaemi SN**, Amerio A. Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review. *J Affect Disord*. 2021 Jan 15;279:473-483.
121. Amerio A, Russo D, Miletto N, Aguglia A, Costanza A, Benatti B, Odone A, Barroilhet SA, Brakoulias V, Dell'Osso B, Serafini G, Amore M, **Ghaemi SN**. Polypharmacy as maintenance treatment in bipolar illness: A systematic review. *Acta Psychiatr Scand*. 2021 Sep;144(3):259-276
122. Selker HP, Cohen T, D'Agostino RB, Dere WH, **Ghaemi SN**, Honig PK, Kaitin KI, Kaplan HC, Kravitz RL, Larholt K, McElwee NE, Oye KA, Palm ME, Perfetto E, Ramanathan C, Schmid CH, Seyfert-Margolis V, Trusheim M, Eichler HG. A Useful and Sustainable Role for N-of-1 Trials in the Healthcare Ecosystem. *Clin Pharmacol Ther*. 2021 Sep 22;10.1002/cpt.2425
123. **Ghaemi SN**. Symptomatic versus disease-modifying effects of psychiatric drugs. *Acta Psychiatr Scand*. 2022 Jun 2
124. **Ghaemi SN**. Drug discovery in psychiatry: Rethinking conventional wisdom. *Canadian Journal of Psychiatry*, 2022, in press.
125. **Ghaemi SN**. The need for non-profit psychiatric drug discovery and development. *Journal of Clinical Psychopharmacology*, 2022, in press.
126. **Ghaemi SN**, Angst J, Vohringer PA, Youngstrom EA, Phelps J, Mitchell PB, McIntyre RS, Bauer M, Vieta E, Gershon S. Clinical Research Diagnostic Criteria (CRDC) for bipolar illness: Rationale and validity. *International Journal of Bipolar*

Disorders, 2022, in press.

Book chapters

1. **Ghaemi SN**, Sachs GS, Baldassano CF. Treatment-resistant bipolar disorder: clinical aspects and management. In: Pollack M, Otto M, Rosenbaum JF, editors. *Challenges in Psychiatric Treatment: Pharmacologic and Psychosocial Strategies*. New York: Guilford Publications; 1996 p. 53-88.
2. **Ghaemi SN**, Irizarry MC, Joseph AB. The effect of psychological stress on neurological disorders. In: Hubbard JR, Workman EA, editors. *The Medical Effects of Stress*. Boca Raton, FL: CRC Press; 1997.p.165-83.
3. Goodwin FK, **Ghaemi SN**. Future directions in mood disorder research. In: Honig A, van Praag HM, editors. *Depression: Neurobiological, Psychopathological, and Therapeutic Advances*. London: John Wiley and Sons; 1997.p.627-43.
4. Goodwin FK, **Ghaemi SN**. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe. *Australian and New Zealand Journal of Psychiatry* 1999;33(suppl):S54-64.
5. **Ghaemi SN**. Bipolar disorder. In: Stern TA, Herman JB, editors, *Psychiatry Update and Board Preparation*. New York, McGraw-Hill; 2000.p. 113-20.
6. **Ghaemi SN**. Lithium. In: Stern TA, Herman JB, editors, *Psychiatry Update and Board Preparation*. New York: McGraw-Hill; 2000.p. 365-8.
7. Goodwin FK, **Ghaemi SN**. The difficult-to-treat patient with bipolar disorder. In: Dewan MJ, editor. *The difficult-to-treat psychiatric patient*. Washington, DC: American Psychiatric Press; 2000.p. 7-40.
8. FK Goodwin, **SN Ghaemi**. An introduction and history of affective disorders. In: *Oxford Textbook of Psychiatry, Volume 1*. 2000.p. 677-80.
9. **Ghaemi SN**, Ko JY. Polypharmacy of bipolar disorder. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p. 35-78.
10. **Ghaemi SN**. “All the worse for the fishes”: Conceptual and historical background of polypharmacy in psychiatry. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p.1-34.
11. **Ghaemi SN**. “Heroic” measures: Cultural aspects of polypharmacy. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p. 311-22.
12. **Ghaemi SN**. “Our pills and potions”: Conclusions about polypharmacy in psychiatry. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p. 323-34.
13. **Ghaemi SN**, Appleton A. Polypharmacy of depression. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p. 79-100.
14. Pillay SS, Ghaemi SN. The psychology of polypharmacy. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p. 299-310.
15. Hewitt HE, Walsh J, **Ghaemi SN**. Psychosocial aspects of polypharmacy: The social work perspective. In: Ghaemi SN, Editor. *Polypharmacy in Psychiatry*. New York: Marcel Dekker; 2002.p. 245-70.
16. **Ghaemi SN**, Ko JY, Goodwin FK. Diagnostico erroneo, empleo de antidepresivos y trastorno del espectro bipolar. In: Palomo T, Beninger RJ, Jimenez-Arriero MA,

- Huertas E, editors. *El Espectro Bipolar*. Madrid: Fundacion Cerebro y Mente; 2002.p. 35-58.
17. **Ghaemi SN**. Karl Jaspers and scientific method in psychiatry. In: Wisser R, Ehrlich L. *Jaspers' philosophy: Rooted in the present, paradigm for the future*. Verlag Kongishausen and Neumann, 2003, pp. 187-194.
 18. Price D, **Ghaemi SN**. *Bipolar Disorder*. In: Stern TA, Herman JB, editors. *Psychiatry Update and Board Preparation*, 2nd edition. New York: McGraw-Hill; 2003.
 19. Perlis R, **Ghaemi SN**. *Lithium*. In: Stern TA, Herman JB, editors. *Psychiatry Update and Board Preparation*, 2nd edition. New York: McGraw-Hill; 2003.
 20. **Ghaemi SN**. Other anticonvulsants: Tiagabine, zonisamide oxcarbazepine, and levetiracetam. In: Sadock BJ, Sadock VA, editors. *Kaplan and Sadock's Comprehensive Textbook of Psychiatry*. Baltimore: Lippincott Williams and Wilkins; 2005, volume 2, pp. 2766-2771
 21. **Ghaemi SN**, Rosenquist KJ. *Insight in mood disorders*. In: Davis AS, Amador XF, editors. *Insight and Psychosis*, 2nd edition. Oxford: Oxford University Press; 2004, pp. 101-118.
 22. **Ghaemi SN**, Hsu DJ. Evidence-based treatment of bipolar disorder. In: Stein DJ, Lerer B, Stahl S, editors: *Evidence-based psychopharmacology*. Cambridge: Cambridge University Press; 2005, pp. 22-55.
 23. **Collaborator**. *Manic-depressive Illness*, 2nd Edition, FK Goodwin and KR Jamison, 2007, New York, Oxford University Press.
 24. **Ghaemi SN**. *General Psychopathology: Its main themes, significance, and influence in contemporary psychiatry*. In: Salamun K, Walters G. *The Cambridge Companion to Karl Jaspers*. Cambridge: Cambridge University Press. 2012
 25. Smith DJ, Whitham EA, **Ghaemi SN**. *Bipolar Disorder*. In: *Handbook of Clinical Neurology* 2012 Vol. 106, pp. 251-263.
 26. **Ghaemi, SN**. The meaning of mania. In: Fulford KWM, Davies M, Gipps R, Graham G, Sadler J, Stanghellini G, Thornton T, editors. *Oxford Handbook of Philosophy and Psychiatry*. Oxford: Oxford University Press; 2013, pp. 803-819.
 27. **Ghaemi, SN** (2015). *Biomedical Reductionist, Humanist, and Biopsychosocial Models in Medicine*. In: Schramme, T., Edwards, S. (eds) *Handbook of the Philosophy of Medicine*, Springer, Dordrecht, pp. 1-19.

Book Reviews

1. **Ghaemi SN**. *Perspectives on the mind: Review of Hundert E, Philosophy, Psychiatry, and Neuroscience*. *Jefferson Journal of Psychiatry*. Summer, 1992.
2. **Ghaemi SN**. *In search of the roots of psychiatry: Review of Havens L, Approaches to the Mind*. *Jefferson Journal of Psychiatry*. Winter, 1992.
3. **Ghaemi SN**. Book review. *Insight and Psychosis*. Amador XF, David AS, editors. *Psychological Medicine* 2001;31:1317-22.
4. **Ghaemi SN**. *Karl Jaspers: A biography*, by Suzanne Kirkbright. *Metapsychology online book reviews*. www.mentalhelp.net, 2005
5. **Ghaemi SN**. *American mania*, by Peter Whybrow. *Metapsychology online book reviews*. www.mentalhelp.net, 2005
6. **Ghaemi SN**. *The lobotomist*, by Jack El-Hai. *Metapsychology online book reviews*. www.mentalhelp.net, 2005

7. **Ghaemi SN.** Clinical psychiatry in imperial Germany, by Eric Engstrom. Metapsychology online book reviews. www.mentalhelp.net, 2005
8. **Ghaemi SN.** The hypomanic edge, by John Gardner. Metapsychology online book reviews. www.mentalhelp.net, 2005
9. **Ghaemi SN.** The truth about the drug companies, by Marcia Angell. Metapsychology online book reviews. www.mentalhelp.net, February 2006

Other Publications (editorials, letters, essays)

1. **Ghaemi SN.** Divided we stand. *Psychiatric News*. July 16, 1993. 28:14.
2. **Ghaemi SN, Irizarry MC.** Parasomnias as neuropsychiatric complications of electrical injury (letter). *Psychosomatics* 1995; 36:416.
3. **Ghaemi SN, Irizarry MC.** Exacerbation of paresthesias as a side effect of the new antidepressant, nefazodone (letter). *Canadian Journal of Psychiatry* 1995; 40:499-500.
4. **Ghaemi SN, Sachs GS, Truman CJ, Gelenberg AJ, Rosenbaum JF.** RBC: plasma lithium ratio and susceptibility to early relapse following lithium reduction. *Psychopharmacology Bulletin* (1995 NCDEU Abstracts);31:572.
5. Baldassano CB, **Ghaemi SN.** Generalized edema with risperidone:divalproex sodium treatment (letter). *Journal of Clinical Psychiatry* 1996; 57:422.
6. **Ghaemi SN, Kirkwood CK.** Elevation of nortriptyline plasma levels following cotreatment with paroxetine and thioridazine (letter). *Journal of Clinical Psychopharmacology*, 1998;18:342-343.
7. **Ghaemi SN, Ko JY.** Tardive dyskinesia with quetiapine (letter). *American Journal of Psychiatry* 2001; 158:1737.
8. Rosenquist KJ, Walker SS, **Ghaemi SN.** Tardive dyskinesia and ziprasidone (letter). *American Journal of Psychiatry* 2002; 159:1436.
9. Soldani F, **Ghaemi SN, Tondo L, Akiskal HS, Goodwin FK.** Relapse after antidepressant discontinuation (letter). *Am J Psychiatry*. 2004 Jul;161(7):1312-3
10. **Ghaemi SN, Goodwin FK.** Antidepressants for bipolar depression (letter). *Am J Psychiatry*. 2005 Aug;162(8):1545-6
11. **Ghaemi SN, Hundert EH.** The ethics of research in mental illness. *The California Journal of the National Alliance for the Mentally Ill*, 1994; 5:47-50.
12. **Ghaemi SN.** The use of antidepressants in bipolar disorder and the role of insight. *The Network: Virginia Alliance for the Mentally Ill Newsletter*, December 1996; 12:4-12
13. **Ghaemi SN.** The use of antidepressants in bipolar disorder and the role of insight. *The AMI/FAMI Reporter*, March/April 1997
14. **Ghaemi SN.** Is bipolar disorder underdiagnosed? Are antidepressants overutilized? *Smooth Sailing: Newsletter of the Depression and Related Affective Disorders (DRADA)*, Winter 1997.
15. **Ghaemi SN.** 'Tis the season to be SAD. *Excellence in Healthcare. The George Washington University Medical Faculty Associates Newsletter*. December 1997/January 1998.
16. **Ghaemi SN.** Novel anticonvulsants: New generation of mood stabilizers? Part I. *International Drug Therapy Newsletter* 1999;34:25-29.
17. **Ghaemi SN.** Novel anticonvulsants: New generation of mood stabilizers? Part II. *International Drug Therapy Newsletter* 1999;34:33-37.

18. **Ghaemi SN.** Do atypical antipsychotic agents have antidepressant properties? *International Drug Therapy Newsletter* September 1999;34:68-70
19. **Ghaemi SN.** Antidepressants and bipolar disorder: Part I. Antidepressants and bipolar disorder: Are antidepressants effective and safe in acute bipolar depression? *International Drug Therapy Newsletter* 2000;35:25-28.
20. **Ghaemi SN.** Antidepressants and bipolar disorder: Part II. Do antidepressants prevent depression in bipolar disorder? *International Drug Therapy Newsletter* May 2000;35:33-37.
21. **Ghaemi SN.** Update on suicide risk factors: an interview with S. Nassir Ghaemi, MD. *Currents in Affective Illness* 2000;19:5-12.
22. Rosenquist KJ, Sporn J, Sambur MR, **Ghaemi SN.** Novel dopamine agonists in the treatment of mood disorders: a review of the literature. *International Drug Therapy Newsletter* 2002;37:57-64.
23. Kupfer DJ, Findling RL, Geller B, **Ghaemi SN.** Treatment of bipolar disorder during childhood, adolescent, and young adult years. *Journal of Clinical Psychiatry Audiograph Series*, Vol. 5, No. 5, March, 2002
24. **Ghaemi SN,** Hsu DJ. Long-term management of bipolar disorder: What does the research say? *Psychiatric Medicine Reports*. Vol 1, Number 1, July 2003, pp 1-12.
25. **Ghaemi SN,** Hsu DJ. Novel maintenance treatment for bipolar disorder: A review of recent olanzapine and lamotrigine studies. *International Drug Therapy Newsletter* in press.
26. **Ghaemi SN.** Prescribing antidepressants for depression in bipolar disorder – Point/Counterpoint. *Psychiatric Times*, August 2004, p. 88-93.
27. **Ghaemi SN.** Pro: Antidepressants are involved in rapid cycling. *The Journal of Bipolar Disorders: Reviews and Commentaries*, 2004, 3(2): 3,14,16-17.
28. **Ghaemi SN.** Foreword. For *Why am I still depressed?* By Jim Phelps MD. New York: McGraw-Hill, 2006.
29. **Ghaemi SN,** Filkowski MM. Antidepressants and Bipolar Disorder: What Do Recent Studies Tell Us? *Psychiatric Times*, May 2006, p.66-70.
30. **Ghaemi SN.** Bipolar personality disorder: A clinical picture, not a disease. *The Journal of Bipolar Disorders*, September 2006; 3:3.
31. **Ghaemi SN.** The newest mania: seeing disease mongering everywhere. *PLoS Med.* July 25 2006;3:e319; author reply e320.
32. **Ghaemi SN.** Sherman's Demons. *Atlanta* magazine, November 2006, p.76-82.
33. Wingo AP, **Ghaemi SN.** STAR*D level IV methodology (letter). *Am J Psychiatry.* 2007;164:681
34. Rakofsky JJ, **Ghaemi SN.** Is aripiprazole an efficacious adjunct for unipolar depression? *J Clin Psychiatry.* 2008 Jun;69(6):1021.
35. Sparkhawk, R. **Ghaemi SN.** CALM: A mnemonic for treatment options for bipolar disorder. *Prim Care Companion J Clin Psychiatry.* 2008;10(6):485-6.
36. **Ghaemi SN.** Reliability, not overdiagnosis. *J Clin Psychiatry.* 2009 Apr;70(4):603-4.
37. **Ghaemi SN.** The rise and fall of the biopsychosocial model. *Br J Psychiatry.* 2009 Jul;195(1):3-4.
38. **Ghaemi SN.** From BALANCE to DSM-5: taking lithium seriously. *Bipolar Disord.* 2010 Nov;12(7):673-7.
39. **Ghaemi SN,** Vöhringer PA. The heterogeneity of depression: an old debate renewed. *Acta Psychiatrica Scandinavica* 2011; 124: 497.

38. **Ghaemi SN.** Antidepressants in bipolar depression: the clinical debate. *Australian & New Zealand Journal of Psychiatry* 2012 46(4) 298–301.
39. Koukopoulos A, Sani G, **Ghaemi SN.** Mixed features of depression: Why DSM-5 is wrong (and so was DSM-IV). *Br J Psychiatry.* 2013 Jul;203(1):3-5.
40. **Ghaemi SN.** Taking disease seriously in DSM. *World Psychiatry.* 2013 Oct;12(3):210-2.
41. Barroilhet S, Vöhringer PA, **Ghaemi SN.** Borderline versus bipolar: differences matter. *Acta Psychiatr Scand.* 2013 Nov;128(5):385-6.
42. **Ghaemi SN.** Psychopathology for what purpose? *Acta Psychiatr Scand.* 2014 Jan;129(1):78-9.
43. **Ghaemi SN.** The “pragmatic” secret of DSM revisions. *Aust N Z J Psychiatry.* 2014 Feb;48(2):196-7.
44. **Ghaemi SN.** DSM-5 and the miracle that never happens. *Acta Psychiatr Scand.* 2014 Mar 17, epub ahead of print
45. **Ghaemi SN.** The psychiatric journal editor and the future. *Acta Psychiatr Scand.* 2015 Dec; 132: 421.
46. **Ghaemi SN.** Bipolar vs. borderline – diagnosis is prognosis once again. *Acta Psychiatr Scand.* 2016 Mar; 133 (3): 171-3.
47. Amerio A, Tonna M, Odone A, **Ghaemi SN.** Comorbid bipolar disorder and obsessive-compulsive disorder: an old debate renewed. *Psychiatry Investig.* 2016 May; 13 (3) 370-1.
48. Tonna M, Amerio A, Odone A, Stubbs B, **Ghaemi SN.** Comorbid bipolar disorder and obsessive-compulsive disorder: state of the art in pediatric patients. *Shanghai Arch Psychiatry* 2015 Dec 25; 27 (6) 386-7.
49. **Ghaemi SN.** A new drug nomenclature for psychiatry – prospects and hazards. *Br J Clin Pharmacol.* 2017 Aug; 83(8): 1617-1618.
50. Amerio A, Tonna M, Odone A, Stubbs B, **Ghaemi SN.** Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry. *Aust N Z J Psychiatry.* 2016 Jul; 50 (7): 699-700.
51. **Ghaemi SN.** Utility without validity is useless. *World Psychiatry.* 2016 Feb;15(1):35-7
52. **Ghaemi SN.** After the failure of DSM: Clinical research on psychiatric diagnosis. *World Psychiatry.* 2018 Oct;17(3):301-302
53. Amerio A, Tonna M, Prelati M, **Ghaemi SN.** Comorbid bipolar and obsessive-compulsive disorders: A commentary. *Bipolar Disord.* 2019;21(4):378-379.
54. Amerio A, Starace F, Costanza A, Serafini G, Aguglia A, Odone A, **Ghaemi SN,** Amore M. Putting Codman's lesson to work: measuring and improving the quality of Italian mental health care. *Acta Psychiatr Scand.* 2020;141(1):91-92
55. DiCarlo JL, **Ghaemi SN.** Digital mania: A novel presentation. *Bipolar Disord.* 2020 Nov;22(7):764.